نتائج البحث - "Bortezomib/pharmacology"

المساهمون: Ki Sun Jung, Kihyun Kim, Hyo Jung Kim, Sung Hyun Kim, Jeong-Ok Lee, Jin Seok Kim, Je-Jung Lee, Hyeon-Seok Eom, Chang-Ki Min, Ho-Jin Shin, Kim, Jin Seok

العلاقة: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA; J04262; OAK-2022-03880; https://ir.ymlib.yonsei.ac.kr/handle/22282913/190217Test; https://www.sciencedirect.com/science/article/pii/S2152265019320658Test; T9992020442; CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, Vol.20(2) : E97-E104, 2020-02

الإتاحة: https://doi.org/10.1016/j.clml.2019.10.017Test
https://ir.ymlib.yonsei.ac.kr/handle/22282913/190217Test
https://www.sciencedirect.com/science/article/pii/S2152265019320658Test

View record in BASE

5

Wnt inhibitors reduce the unfolded protein response and enhance bortezomib-induced cell death in multiple myeloma

المؤلفون: Spaan, Ingrid, van Nieuwenhuijzen, Niels, Kimman, Thomas, Rockx-Brouwer, Dedeke, Tieland, Ralph G, Maurice, Madelon, Minnema, Monique C, Raymakers, Reinier, Peperzak, Victor

المساهمون: CTI Peperzak, MS Hematologie, Cancer, Infection & Immunity, CMM Groep Maurice, Regenerative Medicine and Stem Cells

مصطلحات موضوعية: Antineoplastic Agents/pharmacology, Bortezomib/pharmacology, Cell Death, Humans, Multiple Myeloma/drug therapy, Unfolded Protein Response, Journal Article

وصف الملف: application/pdf

العلاقة: https://dspace.library.uu.nl/handle/1874/447795Test

الإتاحة: https://dspace.library.uu.nl/handle/1874/447795Test

View record in BASE

النص الكامل

6

دورية أكاديمية

Bortezomib prevents cytarabine resistance in MCL, which is characterized by down-regulation of dCK and up-regulation of SPIB resulting in high NF-κB activity

المؤلفون: Freiburghaus, Catja, Emruli, Venera Kuci, Johansson, Angelica, Eskelund, Christian Winther, Grønbæk, Kirsten, Olsson, Roger, Ek, Fredrik, Jerkeman, Mats, Ek, Sara

المصدر: Freiburghaus , C , Emruli , V K , Johansson , A , Eskelund , C W , Grønbæk , K , Olsson , R , Ek , F , Jerkeman , M & Ek , S 2018 , ' Bortezomib prevents cytarabine resistance in MCL, which is characterized by down-regulation of dCK and up-regulation of SPIB resulting in high NF-κB activity ' , BMC Cancer , vol. 18 , no. 1 , 466 . https://doi.org/10.1186/s12885-018-4346-1Test

وصف الملف: application/pdf

الإتاحة: https://doi.org/10.1186/s12885-018-4346-1Test
https://curis.ku.dk/portal/da/publicationsTest/bortezomib-prevents-cytarabine-resistance-in-mcl-which-is-characterized-by-downregulation-of-dck-and-upregulation-of-spib-resulting-in-high-nfb-activity(76795661-66a2-4aee-a31a-9e90aa7a109d).html
https://curis.ku.dk/ws/files/214341008/document_4_.pdfTest

View record in BASE

7

دورية أكاديمية

Determination of differentially regulated proteins upon proteasome inhibition in AML cell lines by the combination of large-scale and targeted quantitative proteomics

المؤلفون: Matondo, Mariette, I, Marcellin, Marlène, Chaoui, Karima, Bousquet-Dubouch, Marie-Pierre, Gonzalez-De-Peredo, Anne, Monsarrat, Bernard, Burlet-Schiltz, Odile

المساهمون: Institut de pharmacologie et de biologie structurale (IPBS), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Centre National de la Recherche Scientifique (CNRS), The work was supported in part by grants from the Région Midi‐Pyrénées, the “Fondation pour la Recherche Médicale” (programme Grands Equipements), European Fonds (FEDER), Toulouse metropole, “Fond Social Européen” (FSE) and the “Ligue contre le cancer” Grants., We thank Dr. Darragh O'Brien from Institut Pasteur for the careful reading of this manuscript., We thank members of the group for insightful comments related to this work. We would like to thank David Bouyssié for MFPAQ software and technical support. We would like also to thank our collaborators Stephane Manenti, for discussion. We Thanks Pr. Dr. Ruedi Aebersold from IMSB (ETH Zurich) for allowing the SRM measurement on the TSQ Vantage.

المصدر: ISSN: 1615-9853.

مصطلحات موضوعية: Apoptosis, Human acute myeloid leukemia (AML) cells, Proteasome inhibitor, SILAC, Targeted proteomics, Technology, MESH: Acetylcysteine / analogs & derivatives, MESH: Acetylcysteine / pharmacology, MESH: Phosphorylation / drug effects, MESH: Proteasome Endopeptidase Complex / drug effects, MESH: Cell Line, Tumor, MESH: Proteasome Endopeptidase Complex / metabolism, MESH: Proteasome Inhibitors / pharmacology, MESH: Protein Isoforms / genetics, MESH: Apoptosis Regulatory Proteins / genetics, MESH: Protein Isoforms / metabolism, MESH: Transcription Factors / genetics, MESH: Transcription Factors / metabolism, MESH: Interleukins / genetics, MESH: Tumor Suppressor Protein p53 / genetics, MESH: Tumor Suppressor Protein p53 / metabolism, MESH: Apoptosis Regulatory Proteins / metabolism, MESH: Computational Biology, MESH: Bortezomib / pharmacology, MESH: Cell Cycle / drug effects, MESH: Cell Cycle Proteins / genetics, MESH: Cell Cycle Proteins / metabolism, MESH: Cell Differentiation, MESH: Gene Expression Profiling

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/27709814; pasteur-02619400; https://pasteur.hal.science/pasteur-02619400Test; https://pasteur.hal.science/pasteur-02619400/documentTest; https://pasteur.hal.science/pasteur-02619400/file/Determination%20of%20differentially%20regulated%20proteins%20upon%20proteasome%20inhibition%20in%20AML%20cell%20lines%20by%20the%20combination%20of%20large%E2%80%90scale%20and%20targeted%20quantitative%20proteomics.pdfTest; PUBMED: 27709814; PUBMEDCENTRAL: PMC5396343

الإتاحة: https://doi.org/10.1002/pmic.201600089Test
https://pasteur.hal.science/pasteur-02619400Test
https://pasteur.hal.science/pasteur-02619400/documentTest
https://pasteur.hal.science/pasteur-02619400/file/Determination%20of%20differentially%20regulated%20proteins%20upon%20proteasome%20inhibition%20in%20AML%20cell%20lines%20by%20the%20combination%20of%20large%E2%80%90scale%20and%20targeted%20quantitative%20proteomics.pdfTest

View record in BASE

8

دورية أكاديمية

Effects of Cellular Pathway Disturbances on Misfolded Superoxide Dismutase-1 in Fibroblasts Derived from ALS Patients.

المؤلفون: Keskin, Isil, Forsgren, Elin, Lange, Dale J, Weber, Markus, Birve, Anna, Synofzik, Matthis, Gilthorpe, Jonathan D, Andersen, Peter M, Marklund, Stefan L

المصدر: PLOS ONE 11(2), e0150133 (2016). doi:10.1371/journal.pone.0150133

مصطلحات موضوعية: info:eu-repo/classification/ddc/610, Adenine: analogs & derivatives, Adenine: pharmacology, Age of Onset, Aging: metabolism, Amyotrophic Lateral Sclerosis: genetics, Amyotrophic Lateral Sclerosis: metabolism, Amyotrophic Lateral Sclerosis: pathology, Autophagy: drug effects, Autophagy: physiology, Bortezomib: pharmacology, C9orf72 Protein, Case-Control Studies, Cells, Cultured, DNA Repeat Expansion, Electron Transport Complex I: antagonists & inhibitors, Endoplasmic Reticulum Stress, Enzyme-Linked Immunosorbent Assay, Fibroblasts: enzymology, Fibroblasts: pathology, Genotype, Humans, Mutation, Protease Inhibitors: pharmacology, Proteasome Endopeptidase Complex: metabolism, Protein Aggregation, Pathological, Protein Folding, Proteins: genetics

جغرافية الموضوع: DE

العلاقة: info:eu-repo/semantics/altIdentifier/issn/1932-6203; info:eu-repo/semantics/altIdentifier/pmid/pmid:26919046; https://pub.dzne.de/record/138409Test; https://pub.dzne.de/search?p=id:%22DZNE-2020-04731%22Test

الإتاحة: https://doi.org/10.1371/journal.pone.0150133Test
https://pub.dzne.de/record/138409Test
https://pub.dzne.de/search?p=id:%22DZNE-2020-04731%22Test

View record in BASE

9

RFWD2 induces cellular proliferation and selective proteasome inhibitor resistance by mediating P27 ubiquitination in multiple myeloma

المؤلفون: Ting Lu, Li Qiao, Ye Yang, Ye Hu, Wang Wang, Mengjie Guo, Rui Li, Anja Seckinger, Fenghuang Zhan, Dirk Hose, Rongfang Wei, Miaomiao Shao, Chunyan Gu

المساهمون: Hematology, Basic (bio-) Medical Sciences

مصطلحات موضوعية: 0301 basic medicine, Cancer Research, Ubiquitin-Protein Ligases, Multiple Myeloma/drug therapy, Cancer metastasis, Antineoplastic Agents, Aggressive disease, Case-control studies, Gene mutation, Bortezomib, 03 medical and health sciences, 0302 clinical medicine, medicine, Tumor Cells, Cultured, Humans, Ubiquitin-Protein Ligases/genetics, Multiple myeloma, Cyclin-Dependent Kinase Inhibitor p27/genetics, hematology, Philosophy, Ubiquitination, medicine.disease, Prognosis, Proteasome Inhibitors/pharmacology, Gene Expression Regulation, Neoplastic, Transplantation, Survival Rate, 030104 developmental biology, Bortezomib/pharmacology, cell proliferation, Oncology, Drug Resistance, Neoplasm, 030220 oncology & carcinogenesis, Gene Expression Regulation, Neoplastic/drug effects, Proteasome inhibitor, Christian ministry, Multiple Myeloma, Proteasome Inhibitors, Humanities, Resistance (creativity), Antineoplastic Agents/pharmacology, Cyclin-Dependent Kinase Inhibitor p27, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::43f1d396323e359453dbfdfee2d99497Test
https://hdl.handle.net/20.500.14017/4caed97a-4e5f-44c8-9940-e891ed37fe26Test

10

دورية أكاديمية

Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA):health-related quality of life outcomes of a randomised, open-label, phase 3 trial

المصدر: Roussel , M , Moreau , P , Hebraud , B , Laribi , K , Jaccard , A , Dib , M , Slama , B , Dorvaux , V , Royer , B , Frenzel , L , Zweegman , S , Klein , S K , Broijl , A , Jie , K-S , Wang , J , Vanquickelberghe , V , de Boer , C , Kampfenkel , T , Gries , K S , Fastenau , J & Sonneveld , P 2020 , ' Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible ....

مصطلحات موضوعية: Antibodies, Monoclonal/pharmacology, Antineoplastic Combined Chemotherapy Protocols, Bortezomib/pharmacology, Dexamethasone/pharmacology, Female, Humans, Male, Multiple Myeloma/drug therapy, Quality of Life/psychology, Thalidomide/pharmacology

الإتاحة: https://doi.org/10.1016/S2352-3026Test(20)30356-2
http://hdl.handle.net/11370/5c192051-c7f9-4048-baa2-6514c3fa4d8fTest
https://research.rug.nl/en/publicationsTest/bortezomib-thalidomide-and-dexamethasone-with-or-without-daratumumab-for-transplantationeligible-patients-with-newly-diagnosed-multiple-myeloma-cassiopeia(5c192051-c7f9-4048-baa2-6514c3fa4d8f).html

View record in BASE

تنقيح النتائج